胶质瘤异柠檬酸脱氢酶(IDH)突变的影像学预测:系统评价与Meta分析
该系统评价与Meta分析纳入28篇原始文献共2146例胶质瘤患者,评估IDH突变型胶质瘤的影像特征及MRI预测IDH突变的诊断效能,其中18篇文献的汇总敏感度为86%(95%CI 79%-91%)、特异度为87%(95%CI 78%-92%),2-羟基戊二酸磁共振波谱的汇总敏感度96%(95%CI 91%-100%)高于其他影像方法。
要点
- IDH突变型胶质瘤影像表现偏向额叶好发、强化较少、边界清晰、ADC值高、rCBV值低。
- MRI预测胶质瘤IDH突变的汇总敏感度86%(95%CI 79%-91%)、特异度87%(95%CI 78%-92%)。
- 2-羟基戊二酸MRS汇总敏感度96%(95%CI 91%-100%),高于其他影像方法。
核心结论
- IDH突变型胶质瘤的影像表现一致地比IDH野生型胶质瘤侵袭性更低。
- 尽管所用MRI技术多样,MRI仍显示出无创预测胶质瘤IDH突变的潜力。
- 2-羟基戊二酸MRS的汇总敏感度高于其他影像方法。
研究设计与样本
- 系统评价与Meta分析,检索Ovid-MEDLINE与EMBASE截至2017年10月10日的文献。
- 共纳入28篇原始文献、2146例胶质瘤患者。
- 纳入评估IDH突变型胶质瘤影像特征及MRI预测IDH突变诊断效能的研究。
- 采用双变量随机效应模型计算汇总敏感度、特异度及其95%CI。
- 诊断效能Meta分析纳入18篇原始文献。
关键影像表现/征象
- IDH突变型胶质瘤呈额叶好发。
- IDH突变型胶质瘤强化较少。
- IDH突变型胶质瘤边界清晰。
- IDH突变型胶质瘤ADC值高。
- IDH突变型胶质瘤rCBV值低。
诊断标准与关键数值
- MRI预测胶质瘤IDH突变:汇总敏感度86%(95%CI 79%-91%)。
- MRI预测胶质瘤IDH突变:汇总特异度87%(95%CI 78%-92%)。
- 亚组分析中2-羟基戊二酸MRS的汇总敏感度为96%(95%CI 91%-100%),高于其他影像方法的汇总敏感度。
临床应用与阅片要点
- 阅片时可关注IDH突变型胶质瘤的额叶好发、强化较少、边界清晰、ADC值高及rCBV值低等影像特征。
- MRI可用于无创预测胶质瘤IDH突变,其诊断效能处于临床可接受范围。
- 2-羟基戊二酸MRS在预测IDH突变方面汇总敏感度高于其他影像方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the imaging features of isocitrate dehydrogenase (IDH) mutant glioma and to assess the diagnostic performance of magnetic resonance imaging (MRI) for prediction of IDH mutation in patients with glioma.
METHODS: A systematic search of Ovid-MEDLINE and EMBASE up to 10 October 2017 was conducted to find relevant studies. The search terms combined synonyms for 'glioma', 'IDH mutation' and 'MRI'. Studies evaluating the imaging features of IDH mutant glioma and the diagnostic performance of MRI for prediction of IDH mutation in patients with glioma were selected. The pooled summary estimates of sensitivity and specificity and their 95% confidence intervals (CIs) were calculated using a bivariate random-effects model. The results of multiple subgroup analyses are reported.
RESULTS: Twenty-eight original articles in a total of 2,146 patients with glioma were included. IDH mutant glioma showed frontal lobe predominance, less contrast enhancement, well-defined border, high apparent diffusion coefficient (ADC) value and low relative cerebral blood volume (rCBV) value. For the meta-analysis that included 18 original articles, the summary sensitivity was 86% (95% CI, 79%-91%) and the summary specificity was 87% (95% CI, 78-92%). In a subgroup analysis, the summary sensitivity of 2-hydroxyglutarate magnetic resonance spectroscopy (MRS) [96% (95% CI, 91-100%)] was higher than the summary sensitivities of other imaging modalities.
CONCLUSIONS: IDH mutant glioma consistently demonstrated less aggressive imaging features than IDH wild-type glioma. Despite the variety of different MRI techniques used, MRI showed the potential to non-invasively predict IDH mutation in patients with glioma. 2-Hydroxyglutarate MRS shows higher pooled sensitivity than other imaging modalities.
KEY POINTS: • IDH mutant glioma showed frontal lobe predominance, less contrast enhancement, well-defined border, high ADC value, and low rCBV value. • The diagnostic performance of MRI for prediction of IDH mutation in patients with glioma is within a clinically acceptable range, the summary sensitivity was 86% (95% CI, 79-91%) and the summary specificity was 87% (95% CI, 78-92%). • In a subgroup analysis, the summary sensitivity of 2-hydroxyglutarate MRS [96% (95% CI, 91-100%)] was higher than the summary sensitivities of other imaging modalities.
引用
- Suh CH, Kim HS, Jung SC, et al. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis. Eur Radiol. 2018. PMID: 30003316. doi:10.1007/s00330-018-5608-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。